HIV-related medical admissions to a South African district hospital remain frequent despite effective antiretroviral therapy scale-up

Medicine (United States)

Volumn 94, Issue 50, 2015, Pages

  Meintjes, Graeme ^a,b,c,d   Kerkhoff, Andrew D ^a,e,f   Burton, Rosie ^b,c   Schutz, Charlotte ^a,b   Boulle, Andrew ^b,g   Van Wyk, Gavin ^h   Blumenthal, Liz ^a   Nicol, Mark P ^b,i   Lawn, Stephen D ^a,b,j  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c Khayelitsha Hospital   (South Africa)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF AMSTERDAM   (Netherlands)

^g WESTERN CAPE DEPARTMENT OF HEALTH   (South Africa)

^h Department of Medicine   (South Africa)

ⁱ NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^j LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIVIRAL THERAPY; ARTICLE; BACTERIAL INFECTION; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDY; CRYPTOCOCCAL MENINGITIS; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HIV TEST; HOSPITAL ADMISSION; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MENINGITIS; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PATIENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUBLIC HOSPITAL; SOUTH AFRICA; TUBERCULOSIS; VENOUS THROMBOEMBOLISM; VIRUS LOAD; COMPLICATION; HEALTH PROMOTION; HIV INFECTIONS; STATISTICS AND NUMERICAL DATA;

ADULT; ANTI-RETROVIRAL AGENTS; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH PROMOTION; HIV INFECTIONS; HOSPITALIZATION; HOSPITALS, DISTRICT; HUMANS; MALE; PROSPECTIVE STUDIES; SOUTH AFRICA;

EID: 84952685088     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000002269     Document Type: Article

References (50)

1. Human Sciences Research Council. South African National HIV Prevalence, Incidence and Behaviour Survey 2012. Cape Town, South Africa: HSRC Press; 2014.
2. Abdool Karim SS, Churchyard GJ, Karim QA, et al. HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response. Lancet. 2009;374:921-933.
3. Bekker LG, Venter F, Cohen K, et al. Provision of antiretroviral therapy in South Africa: the nuts and bolts. Antivir Ther. 2014;19(Suppl 3):105-116.
4. Global Update on the Health Sector Response to HIV, 2014. World Health Organization, Geneva, July 2014.
5. Bor J, Herbst AJ, Newell ML, et al. Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment. Science. 2013;339:961-965.
6. Johnson LF, Mossong J, Dorrington RE, et al. Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies. PLoS Med. 2013;10:e1001418.
7. Republic of South Africa Global AIDS Response Progress Report 2013. South African National AIDS Council, 2013. Accessed at: http://www.sanac.org.za/resources/cat-view/7-publications/9-reports. [Accessed April 18, 2015].
8. Buchacz K, Baker RK, Palella FJ Jr et al. AIDS-defining opportunistic illnesses in US patients, 1994-2007: a cohort study. AIDS. 2010;24:1549-1559.
9. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003;362:22-29.
10. Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. Federation National des Centres de Lutte contre le SIDA. AIDS. 1997;11:F101-F105.
11. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-860.
12. Torres RA, Barr M. Impact of combination therapy for HIV infection on inpatient census. N Engl J Med. 1997;336:1531-1532.
13. Baum SE, Morris JT, Gibbons RV, et al. Reduction in human immunodeficiency virus patient hospitalizations and nontraumatic mortality after adoption of highly active antiretroviral therapy. Mil Med. 1999;164:609-612.
14. Garattini L, Tediosi F, Di Cintio E, et al. Resource utilization and hospital cost of HIV/AIDS care in Italy in the era of highly active antiretroviral therapy. AIDS Care. 2001;13:733-741.
15. Burch VC, Benatar SR. Rational planning for health care based on observed needs. S Afr Med J. 2006;96:796, 800, 802.
16. Colvin M, Dawood S, Kleinschmidt I, et al. Prevalence of HIV and HIV-related diseases in the adult medical wards of a tertiary hospital in Durban, South Africa. Int J STD AIDS. 2001;12:386-389.
17. Ford N, Shubber Z, Meintjes G, et al. Causes of hospital admission among people living with HIV worldwide: a systematic review and meta-analysis. Lancet HIV. 2015;2:e438-e444.
18. National Antenatal Sentinel HIV Prevalence Survey: Western Cape 2013. Western Cape Government, June 2014.
19. Johnson LF. Access to antiretroviral treatment in South Africa, 2004-2011. SA J HIV Med. 2012;13:22-27.
20. Lawn SD, Kerkhoff AD, Burton R, et al. Rapid microbiological screening for tuberculosis in HIV-positive patients on the first day of acute hospital admission by systematic testing of urine samples using Xpert MTB/RIF: a prospective cohort in South Africa. BMC Med. 2015;13:192.
21. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247-254.
22. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81:515-526.
23. Meyer-Rath G, Miners A, Santos AC, et al. Cost and resource use of patients on antiretroviral therapy in the urban and semiurban public sectors of South Africa. J Acquir Immune Defic Syndr. 2012;61:e25-e32.
24. Fox MP, Brennan A, Maskew M, et al. Using vital registration data to update mortality among patients lost to follow-up from ART programmes: evidence from the Themba Lethu Clinic, South Africa. Trop Med Int Health. 2010;15:405-413.
25. Nglazi MD, Kaplan R, Wood R, et al. Identification of losses to follow-up in a community-based antiretroviral therapy clinic in South Africa using a computerized pharmacy tracking system. BMC Infect Dis. 2010;10:329.
26. IeDea, Collaborations ARTC, Avila D, Althoff KN, et al. Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries. J Acquir Immune Defic Syndr. 2014;65:e8-e16.
27. Dart Trial Team. Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts<200 cells/microl. AIDS. 2008;22:237-247.
28. Coetzee D, Hildebrand K, Boulle A, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS. 2004;18:887-895.
29. Bekker LG, Myer L, Orrell C, et al. Rapid scale-up of a communitybased HIV treatment service: programme performance over 3 consecutive years in Guguletu, South Africa. S Afr Med J. 2006;96:315-320.
30. Alvarez GG, Thembela BL, Muller FJ, et al. Tuberculosis at Edendale Hospital in Pietermaritzburg, Kwazulu Natal, South Africa. Int J Tuberc Lung Dis. 2004;8:1472-1478.
31. Mehta U, Durrheim DN, Blockman M, et al. Adverse drug reactions in adult medical inpatients in a South African hospital serving a community with a high HIV/AIDS prevalence: prospective observational study. Br J Clin Pharmacol. 2008;65:396-406.
32. Reid A, Dedicoat M, Lalloo D, et al. Trends in adult medical admissions in a rural South African hospital between 1991 and 2002. J Acquir Immune Defic Syndr. 2005;40:53-56.
33. Fox MP, Rosen S. Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review. Trop Med Int Health. 2010;15(Suppl 1):1-15.
34. Bogart LM, Chetty S, Giddy J, et al. Barriers to care among people living with HIV in South Africa: contrasts between patient and healthcare provider perspectives. AIDS Care. 2013;25:843-853.
35. Miller CM, Ketlhapile M, Rybasack-Smith H, et al. Why are antiretroviral treatment patients lost to follow-up? A qualitative study from South Africa. Trop Med Int Health. 2010;15(Suppl 1):48-54.
36. Ware NC, Wyatt MA, Geng EH, et al. Toward an understanding of disengagement from HIV treatment and care in sub-Saharan Africa: a qualitative study. PLoS Med. 2013;10:e1001369 discussion e1001369.
37. Grimsrud A, Balkan S, Casas EC, et al. Outcomes of antiretroviral therapy over a 10-year period of expansion: a multicohort analysis of African and Asian HIV programs. J Acquir Immune Defic Syndr. 2014;67:e55-e66.
38. Vella V, Govender T, Dlamini S, et al. Retrospective study on the critical factors for retaining patients on antiretroviral therapy in KwaZulu-Natal, South Africa. J Acquir Immune Defic Syndr. 2010;55:109-116.
39. Campion EW. Treating millions for HIV - the adherence clubs of Khayelitsha. N Engl J Med. 2015;372:301-303.
40. Luque-Fernandez MA, Van Cutsem G, Goemaere E, et al. Effectiveness of patient adherence groups as a model of care for stable patients on antiretroviral therapy in Khayelitsha, Cape Town, South Africa. PLoS One. 2013;8:e56088.
41. Gupta A, Wood R, Kaplan R, et al. Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community. PLoS One. 2012;7:e34156.
42. Gupta RK, Lucas SB, Fielding KL, et al. Prevalence of tuberculosis in post-mortem studies of HIV-infected adults and children in resource-limited settings: a systematic review and meta-analysis. AIDS. 2015;29:1987-2002.
43. Osler M, Hilderbrand K, Hennessey C, et al. A three-tier framework for monitoring antiretroviral therapy in high HIV burden settings. J Int AIDS Soc. 2014;17:18908.
44. Suthar AB, Lawn SD, Del Amo J, et al. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med. 2012;9:e1001270.
45. Rangaka MX, Wilkinson RJ, Boulle A, et al. Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised doubleblind, placebo-controlled trial. Lancet. 2014;384:682-690.
46. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. World Health Organization, Geneva, September 2015.
47. Bassett IV, Wilson D, Taaffe J, et al. Financial incentives to improve progression through the HIV treatment cascade. Curr Opin HIV AIDS. 2015;10:451-463.
48. Dewing S, Mathews C, Fatti G, et al. Antiretroviral adherence interventions in Southern Africa: implications for using HIV treatments for prevention. Curr HIV/AIDS Rep. 2014;11:63-71.
49. Harries AD, Zachariah R, Lawn SD, et al. Strategies to improve patient retention on antiretroviral therapy in sub-Saharan Africa. Trop Med Int Health. 2010;15(Suppl 1):70-75.
50. Orrell C, Cohen K, Mauff K, et al. A randomised controlled trial of real-time electronic adherence monitoring with text message dosing reminders in people starting first-line antiretroviral therapy. J Acquir Immune Defic Syndr. 2015;70:495-502.